What is Lyra Therapeutics Operating Cash Flow per Share?
Lyra Therapeutics's operating cash flow per share for the
three
months ended in Mar. 2024 was $-0.35.
Lyra Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.24.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 19.80% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 1.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Lyra Therapeutics's Operating Cash Flow per Share or its related term are showing as below:
LYRA'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -23.3 Med: 13.2 Max: 19.8
Current: 19.8
During the past 6 years, Lyra Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 19.80% per year. The lowest was -23.30% per year. And the median was 13.20% per year.
LYRA's 3-Year OCF Growth Rate is ranked better than 68.21% of 1233
companies
in the Biotechnology industry
Industry Median: 3.5
vs LYRA: 19.80
Lyra Therapeutics Operating Cash Flow per Share Historical Data
The historical data trend for Lyra Therapeutics's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Lyra Therapeutics Operating Cash Flow per Share Chart
Competitive Comparison of Lyra Therapeutics's Operating Cash Flow per Share
For the Biotechnology subindustry, Lyra Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyra Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyra Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Lyra Therapeutics's Price-to-Operating-Cash-Flow falls into.
Lyra Therapeutics Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Lyra Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.24
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lyra Therapeutics Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Lyra Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Lyra Therapeutics (Lyra Therapeutics) Business Description
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LYRA has been successfully added to your 